Search Results
Your search for The ASCO Post,The ASCO Post matches 17617 pages
Showing 15051 - 15100Patience Remains a Virtue: The Ongoing Quest to Optimize Adjuvant Endocrine Therapy in Breast Cancer
The most recent ASCO Clinical Practice Guideline update—summarized in this issue of The ASCO Post—represents the latest chapter in the ongoing evolution of adjuvant endocrine therapy for hormone-sensitive breast cancer.1 Rather than including a comprehensive review of the 2010 guidelines, this...
FDA Grants Bevacizumab Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for bevacizumab (Avastin) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. “The majority of women with ovarian...
FDA Grants Bevacizumab Priority Review for Certain Types of Cervical Cancer
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for bevacizumab (Avastin) plus chemotherapy in the treatment of women with persistent, recurrent, or metastatic cervical cancer. The designation of Priority...
Study Finds New Genetic Risk Markers in Pancreatic Cancer
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the disease, report scientists from Dana-Farber Cancer Institute and other institutions worldwide. The markers are variations in the inherited DNA...
The Evolving Role of Surgery in Germ Cell Tumors
Over the past several decades, the role of postchemotherapy surgery for advanced testicular cancer has evolved with regard to patient selection, surgical planning, lymph node dissection, and surgical technique. To add clarity to this complex clinical setting, The ASCO Post recently spoke with...
College of American Pathologists Publishes Recommendations for Prostate Cancer Active Surveillance
Recommendations from the United States Preventive Services Task Force and randomized trials have drawn attention to overtreatment of localized, low-risk prostate cancer. PSA screening and changing consensus on PSA testing practices are among the many factors that contribute to the overdiagnosis and ...
Enzalutamide and the Landscape of Castration-Resistant Prostate Cancer: Integrating New Indications With Existing Agents
The androgen receptor axis is a validated target for the treatment of castration-resistant prostate cancer. Several perturbations in this pathway are postulated to lead to androgen-independent growth, including androgen receptor mutation and amplification as well as the autocrine production of...
PREVAIL Trial: Enzalutamide Before Chemotherapy Prolongs Survival in Metastatic Prostate Cancer
The androgen-receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Tomasz M. Beer, MD, of...
EGFR as a Therapeutic Target for Gastroesophageal Cancer—or Is It Really?
The epidermal growth factor receptor (EGFR) gene is often amplified and its protein overexpressed in upper gastrointestinal cancers—and overexpression has prognostic value. With the advent of monoclonal antibodies and tyrosine kinase inhibitors against EGFR, we have witnessed a rash of randomized...
NEPA for Chemotherapy-Induced Nausea and Vomiting: Key Endpoints and Additional Analyses Show Strong Efficacy
For the prevention of chemotherapy-induced nausea and vomiting, NEPA, a novel combination of a neurokinin-1 (NK1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), has been studied in three pivotal trials that were recently published in the Annals of Oncology.1-3 Further...
MASCC Awards Honorary Lifetime Membership
The Multinational Association for Supportive Care in Cancer (MASCC) has awarded Honorary Lifetime Membership status to Hans-Jürg Senn, MD, based on his commitment, vision, and extraordinary service to the Society and its publication Supportive Care in Cancer, according to Society News, the MASCC...
Mucositis Remains a Challenge in Head and Neck Cancer
Chemoradiotherapy for head and neck cancer requires intensive supportive care by a knowledgeable and proactive multidisciplinary team, according to Avraham Eisbruch, MD, Professor of Radiation Oncology at the University of Michigan, Ann Arbor. “Aggressive chemoradiotherapy has improved the cure...
New Research Presented in Wilms Tumor, Pediatric Sarcoma, Head and Neck Cancer, and Non–Small Cell Lung Cancer
In the past few months, numerous presentations from this year’s ASCO Annual Meeting have been covered in depth in the pages of The ASCO Post and online at ASCOPost.com. The brief summaries below capture additional important highlights that have not been covered thus far. We hope you will find them...
Recent FDA Drug Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare B-Cell Lymphomas
Recent approvals announced by the U.S. Food and Drug Administration (FDA) have led to increased treatment options for managing several difficult-to-treat hematologic B-cell cancers. The newly approved drugs and/or their indications include the oral PI3K delta inhibitor idelalisib (Zydelig) for the...
2014 Oncology Meetings
SEPTEMBER American Society for Radiation Oncology Annual MeetingSeptember 14-17 • San Francisco, California For more information: www.astro.org Cancer Medicine and Hematology 2014September 14-19 • Boston, Massachusetts For more information: www.hmscme.com/cancermedicine 18th Annual Meeting:...
NIH Announces Launch of Precision Medicine Trials in Early-Stage Lung Cancer
The National Institutes of Health (NIH) recently announced the launch of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST. The purpose of the trial, which has three components, is to identify patients with early-stage lung cancer whose tumors harbor...
Postmenopausal Breast Cancer Risk Decreases Rapidly After Starting Regular Physical Activity
Postmenopausal women who in the past 4 years had undertaken regular physical activity equivalent to at least 4 hours of walking per week had a lower risk for invasive breast cancer compared with women who exercised less during those 4 years, according to data published recently in Cancer...
Royal Society Presents 2014 Royal Medal to Tony Hunter, PhD, FRS, Salk Professor
Tony Hunter, PhD, FRS, has been awarded the 2014 Royal Medal for Biological Sciences by the Royal Society, an international fellowship of scientists based in the United Kingdom. The award recognizes Dr. Hunter, Director of Salk Institute Cancer Center in San Diego, for his contributions to the...
Expect Questions and Perhaps Unrealistic Expectations
A recent study reporting the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1% for women with stage I and II breast cancer without BRCA mutations runs counter to common perceptions about the risk of contralateral breast cancer among these women and the...
Survival Benefit of Contralateral Prophylactic Mastectomy Less Than 1% at 20 Years, but Numbers of Procedures Have Increased
For women with stage I and II breast cancer without BRCA mutations, the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1%, regardless of age, estrogen receptor status, and cancer stage, according to a decision analysis study using a Markov model to...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Mark Del Beccaro, MD, Named Senior Vice President, Chief Medical Officer of Seattle Children’s Hospital
Seattle Children’s has announced that Mark Del Beccaro, MD, has been appointed as Senior Vice President and Chief Medical Officer (CMO) effective October 1, 2014. Dr. Del Beccaro, who currently serves as Vice President of Medical Affairs, will replace David Fisher, MD, who is retiring. “Mark has...
Peter Pisters, MD, Appointed President and Chief Executive Officer, University Health Network, Canada
Mr. John Mulvihill, Chair of the Board of Trustees of University Health Network (UHN), Canada, and Chair of the Board’s Selection Committee for the President and CEO, recently announced that Peter Pisters, MD, will serve as UHN’s next President and CEO, beginning January 1, 2015. Dr. Pisters is...
September Is Prostate Cancer Awareness Month
In recognition of September as Prostate Cancer Awareness Month, The ASCO Post is pleased to share the following reminders, adapted in part from the American Cancer Society: Prostate cancer is the second most common cancer among men, behind skin cancer, and it affects one in seven men in his...
NIH Awards Two New Grants to Explore the Understanding of Genomics Research in Africa
Two grants totaling more than $300,000 will support studies on genomic literacy among Africans as it relates to research conducted in Africa by African investigators. The 3-year grants are part of the Human Heredity and Health in Africa (H3Africa) program, funded by the National Institutes of...
Gynecologic Cancer Care: Collaboration With Resource-Challenged Ethiopia
Over the past 40 years, largely because of universal Pap screening, cervical cancer deaths have been drastically reduced in the United States and other wealthy industrialized countries. However, cervical cancer is still a leading cause of cancer death among women in resource-challenged areas of the ...
How Pharmaceutical Companies Are Partnering With Patient Advocates to Ensure Access to Oncology Care
Thomas P. Sellers, MPA, has been a tireless advocate for patients’ rights for more than 20 years. A 15-year prostate cancer survivor and only child, Mr. Sellers said it was his mother’s death from lung cancer when she was 51, followed by the death of his father from glioblastoma multiforme that led ...
Identifying Impending Death Helps Patients and Caregivers
Significant weight loss, cachexia, and being bedbound signal that a cancer patient is dying. However, identifying the specific signs that give physicians the ability to predict death is not well described in the literature. To better understand why predicting death is an important part of the care...
ASTRO Awards $35,500 in Individual Grants to 43 Researchers
The American Society for Radiation Oncology (ASTRO) has selected 43 recipients to receive a total of $35,500 for the 2014 Annual Meeting Abstract Awards. The awardees will be recognized at ASTRO’s 56th Annual Meeting. ASTRO’s 56th Annual Meeting, takes place San Francisco’s Moscone Center,...
Program Offers Unique Intervention for Acute Promyelocytic Leukemia
If Anand P. Jillella, MD, has his way, no future patient with acute promyelocytic leukemia (APL) will experience a delay in treatment or lack for an expert consult—and few, if any, will die of this condition. Mortality from APL is much higher than most oncologists think, especially during the first ...
Failure of IGF-1R Inhibitor Figitumumab in Advanced Nonadenocarcinoma Non–Small Cell Lung Cancer
The vast majority of non–small cell lung cancer (NSCLC) patients present with advanced disease, and many will develop metastases after primary curative therapy. Until recently, despite its low efficacy, chemotherapy remained the only treatment modality in metastatic NSCLC. Within the past decade,...
Leaders in Health Disparities Honored
The W. Montague Cobb/National Medical Association (NMA) Health Institute (Cobb Institute) was established by the National Medical Association to develop, evaluate, and implement strategies to promote wellness and eliminate health disparities and racism in medicine. The Institute recently celebrated ...
AACI Members Elect New Leadership, Members to Board of Directors
The Association of American Cancer Institutes (AACI) has announced the election of Stanton L. Gerson, MD, as Vice-President/President-Elect for a 6-year term, effective in October 2014. Dr. Gerson is the Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology,...
Palbociclib Expanded Access Program Open to Eligible Breast Cancer Patients
Pfizer Inc announced that the company has initiated a multicenter, open-label expanded access program in the United States for the investigational oral CDK 4/6 inhibitor, palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for postmenopausal...
The Role of Integrated Palliative Care in Radiation Oncology
Three years ago, Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, launched a Supportive and Palliative Radiation Oncology (SPRO) program to integrate generalist palliative oncology services, including the physical, psychosocial, and spiritual aspects of care, into radiation...
Expert Point of View: Wyndham H. Wilson, MD, PhD
Since the presentation on mediastinal lymphoma at the Pan Pacific Lymphoma Conference, Wyndham H. Wilson, MD, PhD, Chief of the Hematological Malignancies Therapeutics Section, Metabolism Branch, Cancer Research Center, of the National Cancer Institute in Bethesda, Maryland, offered The ASCO Post...
FDA Approves Bortezomib Retreatment in Patients With Multiple Myeloma
The U.S. Food and Drug Administration has approved bortezomib (Velcade) for the retreatment of adult patients with multiple myeloma who had previously responded to bortezomib therapy and relapsed at least 6 months following completion of prior bortezomib treatment. The labeling update includes...
FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer
The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...
FDA Grants Fast Track Designation to Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
The U.S. Food and Drug Administration has granted Fast Track designation to pacritinib for the treatment of intermediate- and high-risk myelofibrosis, including patients with disease-related thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are suboptimally...
FDA Approves First Noninvasive DNA Screening Test for Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or...
Systematic Model Identifies Factors Associated With Adherence in Prostate Cancer Prevention Trial
Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo an end-of-study biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The Prostate Cancer Prevention Trial...
Understanding the Impact of Results From CALGB/ SWOG 80405 and Other New Data in Colorectal Cancer
The Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) 80405 trial, presented during the Plenary Session at this year’s ASCO Annual Meeting, demonstrated that cetuximab (Erbitux) and bevacizumab (Avastin) confer similar benefits as first-line treatment with chemotherapy for KRAS...
Charles LeMaistre, MD, and Hans Mark, PhD, Named Chancellors Emeritus by the University of Texas System Board of Regents
Two former Chancellors, Charles LeMaistre, MD, and Hans Mark, PhD, were recently given the honorific title Chancellors Emeritus by the University of Texas System Board of Regents. “Charles LeMaistre and Hans Mark were visionary chancellors who expanded the UT System into new directions that...
Emerging Approaches in Acute Myeloid Leukemia
With the emergence of molecular diagnostics and new therapeutics, the treatment of acute myeloid leukemia (AML) is entering a new era. Hugo F. Fernandez, MD, Associate Chief of Blood and Marrow Transplantation at Moffitt Cancer Center in Tampa, Florida, spoke with The ASCO Post about how he...
Treating Multiple Myeloma in 2014
The field of multiple myeloma is rapidly changing, and the shifts that are occurring impact the management of these patients, from initial diagnosis through multiple relapses. At the 9th Annual New Orleans Summer Cancer Meeting, Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant...
September Is Ovarian Cancer Awareness Month
In recognition of September as Ovarian Cancer Awareness month, David A. Fishman, MD, Director of the Mount Sinai Ovarian Cancer Risk Assessment Program and Professor and Fellowship Director in the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine at...
Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma
Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the...
Expert Point of View: Richard L. Schilsky, MD
Information on the drivers of cancer care is important in helping to deliver higher-quality and potentially less costly cancer treatments, noted Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, in a commentary accompanying the study by Dotan et al.1 Moreover, practice change can be a complex ...
Stereotactic Body Radiation Therapy an Effective Option for Early-Stage Lung Cancer Patients
Stereotactic body radiation therapy (SBRT) is safe and effective in early-stage non–small cell lung cancer (NSCLC), as it confers local control in 90% or more patients with T1 disease, according to Roy Decker, MD, PhD, Associate Professor in the Department of Therapeutic Radiology at Yale Cancer...
St. Jude Children’s Research Hospital Mourns Loss of Friend, Supporter, Robin Williams
St. Jude Children’s Research Hospital acknowledged the death of Robin Williams with the following statement: “On August 11, 2014, the world lost an iconic man and entertainer, and St. Jude Children’s Research Hospital lost an incredible friend and supporter. Robin Williams generously gave his time...
